Dr. Reddy's FY26 Revenue Grows 3.2% Amidst 29% Profit Plunge on One-Offs

Dr. Reddy's Laboratories reported consolidated revenue of ₹33,593.30 Cr for FY26, a 3.2% increase year-on-year.
However, Profit Before Tax (PBT) for the fiscal year declined 29% to ₹5,481.70 Cr, significantly hit by one-off charges.

Reader Takeaway: Revenue grew steadily; sharp profit drop from one-offs clouds outlook.

What just happened (today’s filing)

Dr. Reddy's Laboratories announced its audited financial results for the fiscal year ended March 31, 2026, and the fourth quarter. For the full year, consolidated revenue reached ₹33,593.30 crore, up 3.2% from the previous year.

Profit Before Tax, however, saw a significant drop of 29% year-on-year, falling to ₹5,481.70 crore. This decline was largely attributed to one-off charges, including shelf stock adjustments (SSA), impairments, and provisions.

In the fourth quarter (Q4FY26), revenue declined 11.6% to ₹7,516.20 crore. The PBT for the quarter was sharply down by 90% to ₹199.10 crore, primarily due to these one-off expenses.

The company's board has recommended a final dividend of ₹8 per equity share for FY2025-26, subject to shareholder approval at the upcoming Annual General Meeting.

Why this matters

The significant dip in profitability, especially in Q4, is due to non-recurring items. Investors will be keen to understand the nature and extent of these charges and their potential to recur, as this impacts the company's underlying operational performance and valuation.

The dividend payout signals confidence from the board in the company's future cash flows, despite the short-term profit hit. Management commentary will be crucial to gauge the long-term outlook.

The backstory (grounded)

Dr. Reddy's Laboratories, a prominent Indian pharmaceutical firm, operates globally, developing and marketing a wide array of pharmaceutical products. The company has historically invested in research and development to sustain its product pipeline and market competitiveness.

Recent strategic moves have involved streamlining its portfolio and focusing on core therapeutic areas. The current instance of R&D program discontinuation leading to impairment charges highlights the inherent risks and high costs associated with pharmaceutical research, where many promising candidates fail.

What changes now

• Shareholders are set to receive a final dividend of ₹8 per share if approved.
• The board composition is strengthened with new independent directors, potentially bringing fresh perspectives.
• The appointment of Deloitte Haskins & Sells, LLP as statutory auditors for five years suggests a focus on audit quality and long-term compliance.
• The impact of India's new Labour Codes on operational costs for FY26 has been quantified, indicating a new cost factor to monitor.

Risks to watch

• The significant decline in Profit Before Tax for FY26 (-29%) and Q4FY26 (-90%) due to one-off charges, impairments, and provisions could mask underlying operational performance.
• Discontinuation of specific R&D programs, particularly in CAR-T therapy and a Phase III study, led to substantial impairment charges, indicating potential challenges in its innovation pipeline.
• The company is evaluating the implications of India's new Labour Codes, which resulted in an incremental cost of ₹1,170 million for FY26, adding to operational expenses.

Peer comparison

Dr. Reddy's operates in a highly competitive landscape alongside giants like Sun Pharmaceutical Industries Ltd, Cipla Ltd, and Zydus Lifesciences Ltd. While all are major Indian pharmaceutical players with global operations, their specific therapeutic focus and market strategies vary. Today's results highlight the impact of one-off charges on profitability, a challenge that can affect any company in the sector depending on its R&D pipeline and asset management.

Sun Pharma, the largest peer, reported FY24 revenue of ₹44,991 crore. Cipla posted FY24 revenue of ₹26,331 crore, and Zydus Lifesciences reported ₹17,104 crore in FY24 revenue.

Context metrics (time-bound)

• FY26 Consolidated Revenue: ₹33,593.30 Cr (Standalone).
• FY26 Profit Before Tax: ₹5,481.70 Cr (Standalone) down 29% YoY.
• Q4FY26 Profit Before Tax: ₹199.10 Cr (Standalone) down 90% YoY.
• Incremental cost from Labour Codes in FY26: ₹1,170 million (Standalone).

What to track next

• Shareholder approval for the final dividend of ₹8 per equity share at the AGM.
• Management commentary on the nature and impact of one-off charges during the post-results call.
• Outlook on R&D pipeline progress and any new strategic initiatives.
• Performance of key therapeutic segments contributing to revenue growth.
• Adaptation and cost management related to the implementation of new Labour Codes.
• Discussions at the 42nd Annual General Meeting on July 23, 2026.